Highlights argenx SE

Equities

ARGX

NL0010832176

Real-time Euronext Bruxelles Other stock markets 04:30:21 08/05/2024 pm IST			5-day change	1st Jan Change
370.7 ^EUR	+1.12%		+1.96%	+7.77%

03/05	European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Set to Close Week Lower	MT
17/04	European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Set to Close Week Lower	03/05	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	17/04	MT
Argenx SE Announces Data from its Phase 3 ADHERE Trial Evaluating VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy	16/04	CI
European Equities Traded in the US as American Depositary Receipts Trend Higher in Thursday Trading	04/04	MT
Argenx Se Advances Clinical Development of Efgartigimod in Primary Sjogren's Disease	27/03	CI
Argenx SE Announces Approval of Vyvgart (Efgartigimod Alfa) in Japan for Adults with Primary Immune Thrombocytopenia	26/03	CI
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	21/03	MT
US Futures, European Stocks Rise After Fed Maintains Outlook	21/03	DJ
Global markets live: HP, Moncler, Snowflake, Salesforce, Duolingo...	29/02
Argenx Q4 Loss Widens, Revenue Increases -- Shares Down Pre-Bell	29/02	MT
Argenx SE Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	29/02	CI
Argenx Says FDA Accepted for Priority Review Supplemental BLA for Autoimmune Disease Drug Vyvgart Hytrulo	20/02	MT
Argenx SE Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy	20/02	CI
Halozyme Therapeutics Says Argenx Gets Japan's Approval for Vyvdura to Treat Certain Generalized Myasthenia Gravis Patients	18/01	MT
Japanese Health Regulator Approves Argenx's Generalized Myasthenia Gravis Treatment	18/01	MT
Argenx SE Announces Approval of VYVDURA (efgartigimod Alfa and Hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis	18/01	CI
Exchange-Traded Funds, US Equities Fall Pre-Bell Wednesday as Investors Await US Consumer Confidence, Home Sales Reports	20/12	MT
Argenx SE Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus	20/12	CI
Zai Lab Shares Climb as Vyvgart, Nuzyra, Zejula Added to 2023 China Reimbursement Drug List	14/12	MT
Zai Lab Says China Added Vyvgart, Nuzyra, Zejula to 2023 Reimbursement Drug List	13/12	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights argenx SE

Equities

ARGX

NL0010832176

Highlights

Filters